|

Enasidenib Clinical Trials

9 actively recruiting trials across 7 locations

▼ -1 trial since August 2026

Also known as: AG 221, AG-221, AG221, CC-90007, CC-90007 Free Base +1 more

Pipeline

Phase 1: 2Phase 2: 5Phase 1/2: 2

Top Sponsors

  • National Cancer Institute (NCI)3
  • M.D. Anderson Cancer Center3
  • Memorial Sloan Kettering Cancer Center1
  • Gustave Roussy, Cancer Campus, Grand Paris1
  • Alice Mims1

Indications

  • Cancer9
  • Acute Myeloid Leukemia6
  • Refractory High Risk Myelodysplastic Syndrome1
  • Recurrent High Risk Myelodysplastic Syndrome1
  • IDH2 Gene Mutation1

Houston, Texas2 trials

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

M D Anderson Cancer Center

Phase 1
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2

Other1 trial

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2

Birmingham, Alabama1 trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Tucson, Arizona1 trial

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Banner University Medical Center - Tucson

Phase 2

Aurora, Colorado1 trial

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

University of Colorado

Phase 2

Baltimore, Maryland1 trial

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Johns Hopkins University/Sidney Kimmel Cancer Center

Phase 2

Bethesda, Maryland1 trial

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Memorial Sloan Kettering Basking Ridge

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.